





Clinical significance¹⁻⁵

Determination of total bile acids in human stool plays a major role in diagnosis of bile acid malabsorption leading to various gastrointestinal tract disorders, such as irritable bowel syndrome with diarrhea (IBS-D), bile acid diarrhea (BAD) or Crohn's disease. Approximately 25 – 50% of IBS-D patients and 1% of the population in Western countries suffer from bile acid malabsorption.

DiaSys Total bile acids 21 FS in stool diagnostics 6-12


The gold standard to determine total bile acids in stool, the 7-days 75-selenotaurohomocholic acid retention test (75 SeHCAT), and other currently applied methods, such as liquid and gas chromatography - mass spectrometry (LC-MS and GC-MS) and enzyme-linked immunosorbent assay (ELISA), display many disadvantages.

Disadvantages of currently applied methods	Advantages of DiaSys Total bile acids 21 FS
Highly complex	Uncomplicated widely used method
Expensive	Cost-efficient
Time-consuming	Extremely timesaving
Labor-intensive	Convenient and fast workflow
Require special equipment & specialized staff	Applicable on various common clinical analyzers
⁷⁵ SeHCAT includes ingestion of radioactive substance	Non-invasive

Method


Enzymatic cycling method


Two reactions are combined in the new generation enzymatic cycling method. In the presence of Thio-NAD, the enzyme $3-\alpha$ -hydroxysteroid dehydrogenase ($3-\alpha$ -HSD) converts bile acids to 3-ketosteroids and Thio-NADH. The reaction is reversible and $3-\alpha$ -HSD can convert 3-ketosteroids and NADH to bile acids and NAD. In the presence of excess NADH, the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is determined by measuring specific change of absorbance at 405 nm. This cycling reaction leads to significant signal amplification.




Performance characteristics*

Precision			
Within run N = 20	Mean [μmol/L]	SD [μmol/L]	CV [%]
Sample 1	14.7	0.222	1.50
Sample 2	70.8	0.770	1.09
Sample 3	115	2.37	2.06
Total precision N = 80	Mean [μmol/L]	SD [µmol/L]	CV [%]
Sample 1	14.8	0.607	4.09
Sample 2	72.5	2.54	3.51
Sample 3	120	4.13	3.44







Method comparison

Reference ranges		
Female	4.51 – 70.3 μmol/L	
Male	4.34 – 83.8 μmol/L	

Assay features and benefits

- Innovative cycling method
- Ready-to-use, liquid-stable reagents
- Dedicated calibrator for optimal performance
- Multi-parameter controls for convenient workflow
- Wide measuring range $(3.5 \mu mol/L - 130 \mu mol/L)$

- **Excellent precision**
- Long onboard and calibration stability
- No prolonged sample collection
- Faster than current gold standard
- Dedicated CE application for respons®910

Leading technology in fluid-stable reagents from DiaSys

- · More than 30 years experience in development and production of clinical chemistry tests
- · Premium service in technics, applications and after sales
- Quality products made in Germany
- · High performance, ready-to-use reagents with minimized interferences, long shelf life and onboard stability as well as traceability to international references
- · Perfectly matched fluid-stable reagents, calibrators and controls
- · High grade raw materials from traceable origin
- · Processes and resources certified according to ISO 13485, fulfilling highest quality standards
- · Sustainable processes and products preserve the environment

References

- 1.Thomas L. Clinical Laboratory Diagnostics [Internet]. Prof. Lothar Thomas; 2020 [cited 2022 Feb 28]. Available from: https://www.clinical-laboratory-diagnostics-2020.com/.
- 2. James SC, Fraser K, Young W, et al. Concentrations of Fecal Bile Acids in Participants with Functional Gut Disorders and Healthy Controls. Metabolites. 2021;11:612.
- 3.Camilleri M, Busciglio I, Acosta A, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol. 2014;109:1621-30.
- 4. Costa S, Gattoni S, Nicolardi ML et al. Prevalence and clinical features of bile acid diarrhea in patients with chronic diarrhea. J Dig Dis. 2021;22:108–12.

 5. Connors J. Dunn KA. Allott J. et al. The relationship between fecal bile acids and microbiome community structure in pediatric Crohn's disease. ISME J: 2020;14:702–713.
- 6. Walters JRF. Making the Diagnosis of Bile Acid Diarrhea. Am J Gastroenterol. 2020;115:1974-1975.
- 7. Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010 Nov;3(6):349-57
- 8. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1232-9. doi: 10.1016/j.cgh.2013.04.029. Epub 2013 May 2. PMID: 23644387; PMCID: PMC3783593.
- 9. Vijayvargiya P, Camilleri M, Taylor A, Busciglio I, Loftus EV Jr, Donato LJ. Combined Fasting Serum C4 and Primary Bile Acids From a Single Stool Sample to Diagnose Bile Acid Diarrhea. Gastroenterology. 2020 Nov;159(5):1952-1954.e2. doi: 10.1053/j.gastro.2020.07.001. Epub 2020 Jul 6. PMID: 32645316; PMCID: PMC7680346.

 10. ALPCO. Bile Acids ELISA instruction for use [Internet]. ALPCO; 2022 [cited 2022 March 17]. Available from: https://s3.amazonaws.com/alpco-docs/30/30-BILHU-E01.pdf
- https://cdn.shopify.com/s/files/1/0563/4487/1064/files/Bile_Acids_210610eng.pdf?v=1626198877.
- 12. Immundiagnostik AG. IDK Bile Acids. For the in vitro determination of bile acids in stool [Internet]. IDK AG; 2022 [cited 2022 March 17]. Available from: https://www.immundiagnostik.com/media/pages/testkits/k-7878w/89d499da22-1647482477/k7878w_2022-02_gallensaeuren_stuhl.pdf.



DiaSys
Diagnostic Systems GmbH
Alte Strasse 9
65558 Holzheim
Germany

Phone: +49 6432 9146-0 Fax: +49 6432 9146-32 E-Mail: info@diasys.de www.diasys-diagnostics.com

